注射用头孢他啶阿维巴坦联用注射用硫酸多黏菌素B致肾移植患者肌无力1例分析

doi:10.19803/j.1672-8629.20220446

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (5): 583-584.
DOI: 10.19803/j.1672-8629.20220446

注射用头孢他啶阿维巴坦联用注射用硫酸多黏菌素B致肾移植患者肌无力1例分析

黄少兰^1,3, 杨戈³, 李薇^2,3,*

¹重庆市合川区人民医院药剂科,重庆 401520;
²重庆大学附属肿瘤医院药剂科,重庆 400030;
³陆军军医大学第一附属医院药学部,重庆 400038

收稿日期:2022-07-29 出版日期:2023-05-15 发布日期:2023-05-16
通讯作者: ^*李薇,女,硕士,副主任药师,临床药学。Email: liwei.tmmu@163.com
作者简介:黄少兰,女,硕士,主管药师,临床药学。
基金资助:
重庆市自然科学基金资助项目（cstc2020jcyj-msxmX0337）

One case of muscle loss induced by ceftazidime-avibactam for injection combined with polymyxins B sulfate for injection after renal transplantation

HUANG Shaolan^1,3, YANG Ge³, LI Wei^2,3,*

¹Department of Pharmacy, Hechuan People’s Hospital, Hechuan Chongqing 401520, China;
²Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing 400030, China;
³Department of Pharmacy, the First Hospital Affiliated to Army Medical University, Chongqing 400038, China

Received:2022-07-29 Online:2023-05-15 Published:2023-05-16

摘要/Abstract

摘要： 目的研究注射用头孢他啶阿维巴坦联用注射用硫酸多黏菌素B在肾移植患者中的安全性。方法分析1例29岁女性肾移植患者,予注射用硫酸多黏菌素B+注射用头孢他啶阿维巴坦联合抗感染治疗期间出现肌无力的病例,文献回顾硫酸多黏菌素B与头孢他啶阿维巴坦常见不良反应,分析不良反应发生原因。结果根据Karch和Lasagna评定法与Naranjo不良反应因果关系评估量表,考虑注射用头孢他啶阿维巴坦与注射用硫酸多黏菌素B联用致肌无力可能性大,调整抗感染方案为单用注射用头孢他啶阿维巴坦并调整给药剂量后,患者未再出现相关不良反应。结论联合使用注射用头孢他啶阿维巴坦和注射用硫酸多黏菌素B可能会增加肌无力不良反应发生风险。

关键词: 头孢他啶阿维巴坦, 硫酸多黏菌素B, 注射剂, 肾移植, 肌无力, 感染, 安全性, 药品不良反应

Abstract: Objective To study the safety of ceftazidime-avibactam for injection combined with polymyxins B Sulfate for injection in patients after renal transplantation. Methods The clinical data of a 29-year-old female patient with Klebsiella pneumonia infection after renal transplantation was analyzed, who had been treated with intravenous infusion of polymyxin B sulfate for injection and ceftazidime-avibactam, but her kidney preservation solution was sensitive to colistin and ceftazidime-avibactam. She presented with weakness of muscle during infusion of the sixth dose of ceftazidime-avibactam for injection. The possible causes of adverse reactions were analyzed. Results Based on the Karch and Lasagna method and Naranjo scale, both polymyxin B sulfate and ceftazidime-avibactam were discontinued. These symptoms did not recur after the patient received intravenous infusion of ceftazidime-avibactam alone. Conclusion The combination of ceftazidime-avibactam for injection and polymyxin B sulfate for injection may increase the risk of weakness of muscle.

Key words: ceftazidime-avibactam, polymyxin B sulfate, injection, kidney transplantation, weakness of muscle, infection, safety, adverse drug reaction

中图分类号:

黄少兰, 杨戈, 李薇. 注射用头孢他啶阿维巴坦联用注射用硫酸多黏菌素B致肾移植患者肌无力1例分析[J]. 中国药物警戒, 2023, 20(5): 583-584.

HUANG Shaolan, YANG Ge, LI Wei. One case of muscle loss induced by ceftazidime-avibactam for injection combined with polymyxins B sulfate for injection after renal transplantation[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 583-584.

参考文献

[1] RASHID MU, ROSENBORG S, PANAGIOTIDIS G, et a1. Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiot[J]. Int J Antimicrob Agents, 2015, 46(11): 60-65.
[2] WAGENLENHNER FM, SOBEL JD, NEWELL P, et al.Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections,including acute pyelonephritis: Recapture, a phase 3 randomized trial program[J]. ClinInfect Dis Radiol, 20l6, 63(15): 754-762.
[3] CARMELIY, ARMSTRONG J, LAUD PJ, et a1. Ceftazidime-avibactam or best availble therapy in patients with Ceftazidime-resistant enterobcteriaceae and pseudomonasaeruginosa complicated intra-abdominal infections(reprise):a randomised, pathogen-directed, phase 3 study[J]. Lancet Infect Dis, 2016, 16(6): 661-673.
[4] KUANG H, ZHONG C, WANG Y, et a1. Clinical characteristics and outcomes of patients with multidrug-resistant gram-negative bacterial infections treated with ceftazidime/avibactam[J]. J Glob Antimicrob Resist, 2020, 23: 404-407.
[5] ZHANG M, MA SL, YAN CC, et a1. Analysis of 99 cases of adverse reactions caused by ceftazidime in children[J].Chinese Journal of Rational Drug Use(中国合理用药探索), 2021, 18(5): 33-36.
[6] LIU XD, ZHANG PP, YU D, et a1. Literature analysis of adverse drug reactions induced by ceftazidime-avibactam[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2020, 36(16): 2504-2506.
[7] GATTI M, RASCHI E, PONTI FD.Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis[J]. Eur J Clin Microbiol Infect Dis, 2021, 40(6): 1169-1176.
[8] SOUSA A, PÉREZ-RODRÍGUEZ MT, SOTO A, et al. Effectiveness of ceftazidime-avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae[J]. J Antimicrob Chemother, 2018, 73(11): 3170-3175.
[9] LIU YL, SU NXU T.A case report of ceftazidime accumulation tremor in extremities caused by iodimeporeinduced renal injury[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2021, 30(8): 567-569.
[10] YE C, XIE JY, HU Y, et al.Therapeutic drug monitoring in a antibiotic encepha-lopathy patient induced by ceftazidime involved by clinical pharmacists[J]. Anti-Infection Pharmacy(抗感染药学), 2020, 17(5): 716-719.
[11] TIAN X, ZHANG HM, SUI LR, et al.A case of lip and gingival numbness caused by ceftazidime[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2018, 38(23): 2499-2500.
[12] NATION RL, FORREST A.Clinical pharmacokinetics, pharmacodynamics and toxicodynamics of polymyxins: implications for therapeutic use[J]. Adv Exp Med Biol, 2019, 1145: 219-249.
[13] FALAGAS ME, KASIAKOU SK.Toxicity of polymyxins: a systematic review of the evidence from old and recent studies[J]. Crit Care, 2006, 10(1): R27.
[14] KARCH FE, LASAGNA L.Toward the operational identification of adverse drug reactions[J]. Clin Pharmacol Ther, 1977, 21: 247-25.
[15] NARANIO CA, BUSTO U, SELLERS EM, et al.A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245.
[16] HERRERO FS.Ceftazidime-avibactam[J]. Rev Esp Quimioter, 2022, 35(1): 40-42.
[17] GUO XL, JIAN HC, ZHANG ZQ, et al.Signal mining and analysis of adverse drug reactions associated with nervous system disorders induced by ceftazidime/avibactam based on FAER database[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2022, 42(19): 2046-2050.

注射用头孢他啶阿维巴坦联用注射用硫酸多黏菌素B致肾移植患者肌无力1例分析

One case of muscle loss induced by ceftazidime-avibactam for injection combined with polymyxins B sulfate for injection after renal transplantation

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾茵茵, 张财树, 周颖, 刘丽, 耿颖, 魏宁漪, 钮思静, 陈华, 许卉. 吸入制剂微细粒子空气动力学粒径分布评价方法研究[J]. 中国药物警戒, 2024, 21(2): 141-146.
[2]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[3]	张建, 方慧华. 某院活血化瘀类中药注射剂使用评价标准建立的探索[J]. 中国药物警戒, 2024, 21(2): 185-189.
[4]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[5]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[6]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[7]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[8]	李娜, 郭军, 郭文佳, 吕茵茵, 李彩宏, 牟向东. 奥马珠单抗注射剂治疗哮喘致迟发型皮肤过敏反应1 例分析[J]. 中国药物警戒, 2024, 21(2): 211-212.
[9]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[10]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[11]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[12]	柏兆方, 湛小燕, 姚清, 陈思敏, 赵旭, 肖小河. 中药安全性评价理论创新与技术突破：病证毒理学[J]. 中国药物警戒, 2024, 21(1): 6-14.
[13]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[14]	方志娥, 李承贤, 柏兆方, 赵旭, 王伽伯, 肖小河. 马兜铃酸致肝癌的客观性研究与思考[J]. 中国药物警戒, 2024, 21(1): 20-24.
[15]	张敬升, 冀祖恩, 庞博, 徐英莉, 曹姗, 张宇, 孙绮悦, 孙静, 李舒冉, 张薇, 赵荣华, 崔晓兰. 宣肺败毒方治疗新冠病毒感染的中医学理论探讨及现代药理研究进展[J]. 中国药物警戒, 2024, 21(1): 55-58.